Comprehensive DNA and RNA Profiling in Hematolymphoid Malignancies
Summary
June 25, 2026
Comprehensive DNA and RNA Profiling in Hematolymphoid Malignancies: Enabling Research Focused CGP Approaches with Archer™ FUSIONPlex® and VARIANTPlex® Assays
Hematolymphoid malignancies are characterized by complex genomic landscapes that include single nucleotide variants, small and large insertions and deletions, copy number changes, and oncogenic gene fusions. Increasingly, laboratories are adopting comprehensive genomic profiling (CGP)–style approaches to interrogate both DNA- and RNA‑level alterations in a unified workflow, supporting discovery, classification, and translational research in hematologic cancers.
In this webinar on June 25 at noon ET, Dr. Celeste Eno will discuss research strategies for integrated somatic variant and fusion detection across myeloid and lymphoid malignancies. Drawing on real-world laboratory experience, the session will highlight how Archer™ VARIANTPlex® DNA panels and Archer™ FUSIONPlex® RNA panels can be combined to support flexible, scalable hematologic cancer profiling workflows.
Hematolymphoid malignancies are characterized by complex genomic landscapes that include single nucleotide variants, small and large insertions and deletions, copy number changes, and oncogenic gene fusions. Increasingly, laboratories are adopting comprehensive genomic profiling (CGP)–style approaches to interrogate both DNA- and RNA‑level alterations in a unified workflow, supporting discovery, classification, and translational research in hematologic cancers.
In this webinar on June 25 at noon ET, Dr. Celeste Eno will discuss research strategies for integrated somatic variant and fusion detection across myeloid and lymphoid malignancies. Drawing on real-world laboratory experience, the session will highlight how Archer™ VARIANTPlex® DNA panels and Archer™ FUSIONPlex® RNA panels can be combined to support flexible, scalable hematologic cancer profiling workflows.